• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

    204.36 -1.12 (-0.55%)
    Streaming Delayed Price Updated: 1:54 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,660,061
    Open 205.46
    Bid (Size) 204.13 (120)
    Ask (Size) 204.59 (200)
    Prev. Close 205.48
    Today's Range 200.11 - 207.99
    52wk Range 197.81 - 495.55
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript ↗
    TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire

    Performance

    YTD
    -48.9%
    -48.9%
    1 Month
    -32.1%
    -32.1%
    3 Month
    -34.0%
    -34.0%
    6 Month
    -41.1%
    -41.1%
    1 Year
    -39.9%
    -39.9%

    More News

    Read More
    News headline image
    Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
    From Law Offices of Howard G. Smith
    Via Business Wire
    Alnylam Pharmaceuticals (NASDAQ:ALNY) Plunges After Q2 Revenue Miss and Lowered Full-Year Guidance ↗
    Via Chartmill
    Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth ↗
    Via Chartmill
    Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock ↗
    Via Chartmill
    News headline image
    Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Alnylam Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    What Happens to Stocks After Joining the Nasdaq-100 (History Has a Clear Answer) ↗
    Via The Motley Fool
    Topics Artificial Intelligence Electric Vehicles Initial Public Offering
    ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers ↗
    Via Chartmill
    Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Growth and a Key Technical Setup ↗
    Via Chartmill
    News headline image
    Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
    Via MarketBeat
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
    Via The Motley Fool
    News headline image
    Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
    Via Benzinga
    News headline image
    Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
    Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
    What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 204.36
    When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 07/31/26 01:54 PM ET
    What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 24.29B
    How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
    Alnylam Pharmaceuticals, Inc. - Common Stock has 24B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.